



ODB FORMULARY – EDITION NO. 42, Summary of Changes – November 2015 SUMMARY OF PRODUCT CHANGES

We are pleased to provide you with the Summary of Changes – November 2015 to Edition No. 42 of the Ontario Drug Benefit (ODB) Formulary / Comparative Drug Index (Formulary), which becomes effective November 26, 2015. The updated Edition No. 42 document will be posted on the Ministry’s website: http://www.health.gov.on.ca/en/pro/programs/drugs/edition_42.aspx by November 26, 2015.

The information in this Summary of Changes – November 2015 is based on the decisions made by the Executive Officer, taking into consideration recommendations from the Ministry’s expert advisory committee, the Committee to Evaluate Drugs (CED).

Listing Changes

- 1 new single source product (Aptiom)
- 7 new multiple source drugs (14 individual strengths and/or package sizes)
- 2 new Off-Formulary Interchangeable generic products (2 strengths)
- 1 existing single-source product, funded through the Exceptional Access Program (EAP), with a new pack size (Forteo)
- 1 new single-source product funded through EAP (Firazyr)
- 4 existing EAP products, with new indications (Remicade, Rituxan, Humira, and Mycophenolate mofetil (brand and generic products))

New Single Source Drug Products

Aptiom 200mg, 400mg, 600mg, 800mg Tab

Reason For Use Code #430: As adjunctive therapy in the treatment of adult patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND,

Patients are under the care of a physician experienced in the treatment of epilepsy.

New Multiple Source Drug Products

ACT Latanoprost/Timolol 50mcg/mL & 5mg/mL Oph Sol-2.5mL

Pk	ACV
ACT Solifenacin 5mg, 10mg Tab	ACV
Sandoz Solifenacin 5mg, 10 mg Tab	SDZ
Taro-Temozolomide 5mg, 20mg, 100mg, 140mg, 250mg Cap	TAR
Van-Telmisartan 40mg, 80mg Tab	VAN
Auro-Valganciclovir 450mg Tab	AUR
Pantoprazole Magnesium 40mg Ent Coated Tab	ASP

Existing Exceptional Access Program Product with New Pack Size

Forteo 250mcg/mL Pref Syr-2.4mL Pk – Effective Date: November 17, 2015
For the treatment of osteoporosis, according to specific criteria.

New Exceptional Access Program Product

Firazyr 30mg/3mL Pre-filled Syringe – Effective Date: November 5, 2015
For the treatment of acute attacks of hereditary angioedema (HAE), according to specific criteria.

Existing Exceptional Access Program Product with New Indications

Rituxan 10mg/mL Inj-10mL Vial Pk, 50mL Vial Pk – Effective Date: November 26, 2015
For the treatment of severe non-infectious ocular inflammatory disease (OID), according to specific criteria.

Remicade 100mg/10mL Inj. – Effective Date: November 26, 2015

For the treatment of severe non-infectious ocular inflammatory disease (OID), according to specific criteria.

Humira 40mg/0.8mL – Effective Date: November 26, 2015

For the treatment of severe non-infectious ocular inflammatory disease (OID), according to specific criteria.

Mycophenolate mofetil 250mg, 500mg Cap – Effective Date: November 26, 2015

For the treatment of non-infectious ocular inflammatory disease (OID), according to specific criteria.

The reimbursement criteria for the above products will be included on the list of Frequently Requested Drugs, which can be found on the Ministry's website:

http://www.health.gov.on.ca/en/pro/programs/drugs/pdf/frequently_requested_drugs.pdf

Drug Benefit Prices (DBP) for EAP products can be accessed from the Ministry's website:

http://www.health.gov.on.ca/en/pro/programs/drugs/odbf/odbf_except_access.aspx

The Ministry has posted a new file with the listing changes for download and review (Edition No. 42, Summary of Changes – November 2015). It is accessible from the Ministry's website:

http://www.health.gov.on.ca/en/pro/programs/drugs/edition_42.aspx

In addition, the Formulary, Summaries of Changes and Bulletins, including a searchable electronic version of the Formulary (e-Formulary), are also accessible from the Ministry's website: http://www.health.gov.on.ca/en/pro/programs/drugs/odbf_iformulary.aspx - The e-Formulary will be updated on the effective date – November 26, 2015.

We appreciate your continued cooperation in making these benefit adjustments.